论文部分内容阅读
目的评估ERCC1-mRNA表达水平对于上皮性卵巢癌患者(epithelial ovarian cancer,EOC)含铂类化疗的疗效预测价值。方法收集中国医科大学肿瘤医院2008年至2010年78例含铂化疗的EOC患者的血液及术后标本进行研究,采用RT-PCR的方法检测ERCC1、Bax、Bcl-2基因mRNA水平的表达。分析ERCC1-mRNA表达水平与EOC患者的临床病理特征、无进展生存(PFS)之间的关系。结果 78名入组患者中,ERCC1-mRNA化疗后显著增加组(ERCC1-H,44名患者)与ERCC1-mRNA化疗后变化不明显组(ERCC1-L,34名患者)的PFS差距明显(P<0.05),且化疗后ERCC1-H组Bax基因mRNA水平高于ERCC1-L组(P<0.05),而Bcl-2基因mRNA水平低于ERCC1-L组(P<0.05)。ERCC1-H组的无疾病进展生存期平均为18.5个月,而ERCC1-L组的无疾病进展生存期平均为26.9个月。结论 ERCC1-mRNA的表达可作为卵巢癌铂类药物耐药性与敏感性预测的重要参考。
Objective To evaluate the predictive value of ERCC1-mRNA expression in platinum-based chemotherapy for epithelial ovarian cancer (EOC). Methods Totally 78 blood samples of patients with EOC and platinum-containing chemotherapy were collected from Cancer Hospital of China Medical University from 2008 to 2010. The mRNA expression of ERCC1, Bax and Bcl-2 was detected by RT-PCR. The relationship between the expression of ERCC1-mRNA and the clinicopathologic features and progression-free survival (PFS) of patients with EOC was analyzed. Results There was a significant difference in PFS between the ERCC1-L group (44 patients) and ERCC1-L group (78 patients) in ERCC1-L group <0.05). The mRNA level of Bax gene in ERCC1-H group was higher than that in ERCC1-L group (P <0.05), but the mRNA level of Bcl-2 gene was lower than that in ERCC1-L group (P <0.05). The disease-free survival of patients in ERCC1-H group averaged 18.5 months, while the disease-free survival of patients in ERCC1-L group averaged 26.9 months. Conclusion The expression of ERCC1-mRNA can be used as an important reference for prediction of drug resistance and sensitivity of ovarian cancer platinum-based drugs.